Frontiers in Psychiatry (Jul 2024)

Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

  • Kiflu G. Tesfamicael,
  • Kiflu G. Tesfamicael,
  • Lijun Zhao,
  • Lijun Zhao,
  • Rubén Fernández-Rodríguez,
  • David L. Adelson,
  • Michael Musker,
  • Thomas M. Polasek,
  • Martin David Lewis,
  • Martin David Lewis

DOI
https://doi.org/10.3389/fpsyt.2024.1276410
Journal volume & issue
Vol. 15

Abstract

Read online

AimTo determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.MethodsA comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data.ResultsPatients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU).ConclusionPGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.

Keywords